Tesla, Micron Rise Premarket; Boeing Falls

Tesla, Micron Rise Premarket; Boeing Falls

© Reuters.  © Reuters.

By Peter Nurse

Investing.com — Stocks in focus in premarket trade on Friday, January 8th. Please refresh for updates.

  • Boeing (NYSE:BA) stock fell 0.2% after the aircraft manufacturer agreed to pay more than $2.5 billion in fines and compensation upon reaching a settlement with the U.S. Department of Justice over two plane crashes that killed a total of 346 people and led to the grounding of its 737 MAX jetliner.

  • Micron (NASDAQ:MU) stock rose 3.9% after the tech company reported strong first-quarter results and provided fiscal second-quarter earnings guidance that topped estimates. thanks to a recovery in memory chip demand driven by accelerating fdigitization across the economy.

  • Apple (NASDAQ:AAPL) stock rose 1.1% after the tech giant was linked with South Korea’s Hyundai (OTC:HYMLY) over a potential electric car and battery tie-up.

  • Tesla (NASDAQ:TSLA) stock rose 4.5%, continuing the stock’s surge which resulted in the electric carmaker’s founder, Elon Musk, becoming the world’s richest person on Thursday.

  • Moderna (NASDAQ:MRNA) stock rose 1.9% after the U.K. regulator approved the use of the drugmaker’s Covid-19 vaccine for use in the country, its third option.

  • Pfizer (NYSE:) stock rose 0.3% after the EU agreed a new deal for the pharma giant’s Covid-19 vaccine, developed in conjunction with BioNTech (NASDAQ:BNTX), doubling its stock of the drug. Additionally, a new report suggested this vaccine also works against the new strains of the virus.

  • Chevron (NYSE:CVX) stock rose 2.1% after Piper Sandler (NYSE:PIPR) upgraded its stance on the oil major to ‘overweight’ from ‘neutral’, citing valuation with its stock down 23% over the past year.

  • SolarWinds (NYSE:SWI) stock rose 0.7% after the company, whose software was used as a springboard for a significant breach of U.S. government computers, has hired former U.S. Cybersecurity and Infrastructure Security Agency head Chris Krebs as a consultant.

Original Article

Leave a comment

Send a Comment

Your email address will not be published. Required fields are marked *